Category: esters-buliding-blocks

On June 3, 2010, Mochizuki, Akiyoshi; Nagata, Tsutomu; Kishida, Masanori; Takano, Daisuke; Kanno, Hideyuki published a patent.Electric Literature of 114312-57-1 The title of the patent was Preparation of N-(2-acylaminobenzyl or 2-acylaminoheterocyclylmethyl)thiophene-2-carboxamide derivatives as antithrombotics. And the patent contained the following:

Diamides represented by the general formula [I; ring A = benzene, pyridine, pyridazine, pyrazine, or pyrimidine ring; R1 = H, halo, C1-6 alkyl, halo-C1-6 alkyl, HO, C1-6 alkoxy, halo-C1-6 alkoxy; R2 = H, halo, C1-6 alkyl, halo-C1-6 alkyl, HO, C1-6 alkoxy, halo-C1-6 alkoxy, C1-6 alkylsulfonyloxy, cyano, CO2H, C1-6 alkoxycarbonyl, carboxy-C1-6 alkyl, each (un)substituted CONH2 or NH2, , etc.; T1 = CONR3, NR3CO; R3 = H, C1-6 alkyl; T2 = CR4R5NHCO; R4, R5 = H, C1-6 alkyl; Q1 = C1-6 alkylsulfonylphenyl, N,N-di(C1-6 alkyl)aminocyclohexyl, 2-oxopyrrolidinyl, 2-oxo[1,3]oxazolidinyl, 1,1-dioxo-1λ6-isothiazolidinyl, 1-C1-6 alkylpiperidinyl, etc.; Q2 = a single bond, (un)substituted 1,4-phenylene, piperidine-1,4-diyl, thiazole-2,5-diyl, [1,3,4]thiadiazole-2,5-diyl, pyridine-2,5-diyl; Q3 = each (un)substituted Ph, thienyl, pyrrolyl, or pyridyl] or pharmacol. acceptable salts thereof were prepared These compounds have a potent inhibitory activity on activated blood coagulation factor Xa (FXa) and exhibit quick, sufficient and lasting antithrombotic effect even by oral administration. They are useful for the prevention and/or treatment of thrombus or embolism, more specifically cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary embolism, Buerger disease, deep vein thrombosis, disseminated intravascular coagulation (DIC), thrombus formation after artificial valve/joint replacement, thrombus formation or re-obstruction (clogging) after vascular reconstruction, multiple organ failure (MODS), thrombus formation during extracorporeal circulation, or blood coagulation during blood sampling. Thus, 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxylic acid hydrochloride 260, HOBt 140, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 234 mg, and 320 μL Et3N were added to a solution of 253 mg N-(2-aminobenzyl)-5-chlorothiophene-2-carboxamide in 10 mL DMF and the resulting mixture was stirred at room temperature for 23 h to give, after workup, 262 mg N-[2-[[[(5-Chlorothiophen-2-yl)carbonyl]amino]methyl]phenyl]-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamide (II). II hydrochloride and 4-[[[(5-Chlorothiophen-2-yl)carbonyl]amino]methyl]-3-fluoro-5-[[(5-isopropyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]benzoic acid Me ester (III) inhibited human FXa with IC50 of 1.7 and 0.51 nM, resp. The experimental process involved the reaction of Ethyl 3-fluoro-2-methylbenzoate(cas: 114312-57-1).Electric Literature of 114312-57-1

The Article related to angina pectoris, anticoagulants, brain infarction, diamides role: pac (pharmacological activity), spn (synthetic preparation), thu (therapeutic use), biol (biological study), prep (preparation), uses (uses), disseminated intravascular blood coagulation, embolism, homo sapiens, human, multiple organ failure, myocardial infarction, pulmonary embolism, stroke, thromboangiitis obliterans, thrombus, venous thrombosis and other aspects.Electric Literature of 114312-57-1

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On April 22, 1999, Takahashi, Kanji; Sugiura, Tsuneyuki published a patent.Quality Control of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate The title of the patent was Preparation of aminobutanoic acid derivatives as inhibitors of matrix metalloproteinases. And the patent contained the following:

Aminobutanoic acid derivatives represented by general formula (I) and salts thereof [wherein R1 = CO2R10, CONHOR10, CONHNHR10, (CH2)nSR50, Y-P(:O)(OR51)2; R10 = H, C1-8 alkyl, Ph, phenyl- or C1-8 alkoxy-C1-8 alkyl, PhO2C, PhCH2O2C, C1-8 alkoxycarbonyl; wherein n = 0-3; R50 = H, C1-8 alkyl, C1-8-alkyl-carbonyl, PhCO, SH, C1-8 alkylthio, SPh; R51 = H, C1-8 alkyl, Ph; Y = single bond, CH2, O; R2-R7 = H, C2-8 alkenyl, (un)substituted SH, OH, or NH2, CO2H, C1-8 alkyl-carbonyl, C1-8 alkoxy-carbonyl, (un)substituted carbocyclyl or heterocyclyl, (un)substituted C1-8 alkyl or C2-8 alkenyl; or R3 and R4 or R5 and R6 together represents C1-8 alkylene; or R2 and R3, R4 and R5, or R6 and R7 together represent C2-8 alkylene; when R8 = H, (un)substituted C1-8 alkyl, or C1-8 alkoxy-carbonyl, R9 = (un)substituted carbocyclyl; or when R8 = (un)substituted carbocyclyl or heterocyclyl, R9 = (un)substituted C1-8 alkyl or C1-8 alkoxy, (un)substituted carbocyclyl; M = C1-8 alkylene; J = single bond, O, S, NH, C1-8 alkyl-N] are prepared and claimed. Also claimed are matrix metalloproteinases containing I as the active ingredients and drugs containing I as the active ingredients for the prevention and/or treatment of rheumatism, osteoarthritis, pathol. bone resorption, osteoporosis, periodontal diseases, interstitial nephritis, arteriosclerosis, pulmonary emphysema, hepatic cirrhosis, corneal injury, diseases due to metastasis and infiltration of cancer cells or proliferation thereof, autoimmune diseases (such as Crohn’s disease and Sjogren’s disease), diseases due to transmigration of white blood cells or infiltration thereof, neovascularization, multiple sclerosis, aortic aneurysm, or endometritis. For example, the title compound (II) showed IC50 of 26 nM against human stromelysin. A table and an ampule formulation containing II were described. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Quality Control of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

The Article related to antiarteriosclerotics, antirheumatic agents, antitumor agents, aortic aneurysm, autoimmune disease, bone resorption, cirrhosis, corneal injury, crohn disease, endometritis, interstitial nephritis, leukocyte, metastasis inhibitors, multiple sclerosis, neovascularization, osteoarthritis, osteoporosis, periodontal disease and other aspects.Quality Control of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On December 1, 2013, Eibl, Christoph; Munoz, Lenka; Tomassoli, Isabelle; Stokes, Clare; Papke, Roger L.; Guendisch, Daniela published an article.Computed Properties of 227940-70-7 The title of the article was The 3,7-diazabicyclo[3.3.1]nonane scaffold for subtype selective nicotinic acetylcholine receptor ligands. Part 2: Carboxamide derivatives with different spacer motifs. And the article contained the following:

3,7-Diazabicyclo[3.3.1]nonane (bispidine) based nicotinic acetylcholine receptor (nAChR) ligands, e.g., I, have been synthesized and evaluated for nAChRs interaction. Diverse spacer motifs were incorporated between the hydrogen bond acceptor (HBA) part and a variety of substituted (hetero)aryl moieties. Bispidine carboxamides bearing spacer motifs often showed high affinity in the low nanomolar range and selectivity for the α4β2* nAChR. Compound I and the other two tested compounds with Ki values of about 1 nM displayed the highest affinities for α4β2* nAChR. All evaluated compounds are partial agonists or antagonists at α4β2*, with reduced or no effects on α3β4* with the exception of compound I (agonist), and reduced or no effect at α7 and muscle subtypes. The experimental process involved the reaction of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate(cas: 227940-70-7).Computed Properties of 227940-70-7

The Article related to brain disease, central nervous system agents, central nervous system disease, laburnum anagyroides (seeds and pods), mathematical methods (acd/adme and acd/physchem), nicotinic agonists, nicotinic antagonists, structure-activity relationship and other aspects.Computed Properties of 227940-70-7

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On December 1, 2013, Eibl, Christoph; Tomassoli, Isabelle; Munoz, Lenka; Stokes, Clare; Papke, Roger L.; Guendisch, Daniela published an article.Recommanded Product: tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate The title of the article was The 3,7-diazabicyclo[3.3.1]nonane scaffold for subtype selective nicotinic acetylcholine receptor (nAChR) ligands. Part 1: The influence of different hydrogen bond acceptor systems on alkyl and (hetero)aryl substituents. And the article contained the following:

3,7-Diazabicyclo[3.3.1]nonane is a naturally occurring scaffold interacting with nicotinic acetylcholine receptors (nAChRs). When one nitrogen of the 3,7-diazabicyclo[3.3.1]nonane scaffold was implemented in a carboxamide motif displaying a hydrogen bond acceptor (HBA) functionality, compounds with higher affinities and subtype selectivity for α4β2* were obtained. The nature of the HBA system (carboxamide, sulfonamide, urea) had a strong impact on nAChR interaction. High affinity ligands for α4β2* possessed small alkyl chains, small un-substituted hetero-aryl groups or para-substituted Ph ring systems along with a carboxamide group. Electrophysiol. responses of selected 3,7-diazabicyclo[3.3.1]nonane derivatives to Xenopus oocytes expressing various nAChR subtypes showed diverse activation profiles. Compounds with strongest agonistic profiles were obtained with small alkyl groups whereas a shift to partial agonism/antagonism was observed for aryl substituents. The experimental process involved the reaction of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate(cas: 227940-70-7).Recommanded Product: tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

The Article related to blood-brain barrier, brain, drug transport, homo sapiens, human, lipophilicity, nicotinic receptors role: bsu (biological study, unclassified), biol (biological study), structure-activity relationship, nicotinic receptor-binding and other aspects.Recommanded Product: tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On November 25, 1997, Berryman, Kent Alan; Doherty, Annette Marian; Edmunds, Jeremy John; Patt, William Chester; Plummer, Mark Stephen; Repine, Joseph Thomas published a patent.Quality Control of Methyl 2-(3-formylphenyl)acetate The title of the patent was Preparation of 3,5-diphenyl-2(5H)-furanone derivatives as nonpeptide endothelin I antagonists. And the patent contained the following:

Novel nonpeptide antagonists of endothelin I represented by formula [I; R1 = (un)substituted C3-12 cycloalkyl, Ph substituted with 1-5 substituents, naphthyl or heteroaryl optionally substituted with 1-5 substituents; R2 = C1-12 linear or branched alkyl, C3-12 linear or branched cycloalkyl, aryl optionally substituted with 1-5 substituents, heteroaryl optionally substituted with 1-3 substituents; R3 = (un)substituted C1-12 linear or branched alkyl, (un)substituted C3-12 cycloalkyl, aryl optionally substituted with 1-5 substituents, heteroaryl optionally substituted with 1-3 substituents; R4 = OH, OR5, (CH2)nOR5; wherein R5 = (un)substituted C1-7 alkyl; X = O, S] or tautomeric open chain keto-acids forms thereof or pharmaceutically acceptable salt thereof are prepared Also described are pharmaceutical compositions of the above compounds, which are useful in treating elevated levels of endothelin, acute and chronic renal failure, hypertension, myocardial infarction, myocardial ischemia, cerebral vasospasm, cerebral ischemia, cerebral infarction, cirrhosis, septic shock, congestive heart failure, endotoxic shock, subarachnoid hemorrhage, arrhythmia, asthma, preeclampsia, atherosclerotic disorders including Raynaud’s disease and restenosis, angina, cancer, pulmonary hypertension, ischemic disease, gastric mucosal damage, hemorrhagic shock, ischemic bowel disease, stroke, benign prostatic hyperplasia (BPH), and diabetes. Thus, Me 2-benzoyl-2-phenylacetate derivative (II) and 3,4,5-trimethoxybenzladehyde were refluxed in the presence of NaOMe in MeOH for 18 h and the solution was treated with AcOH and refluxed an addnl. 72 h, followed by saponification of the product with 1N aqueous NaOH and acidification to give 28% I (X = O, R1 = Q, R2 = 3,4,5-trimethoxyphenyl, R3 = 4-methoxyphenyl, R4 = OH). The latter compound in vitro showed an antagonism of endothelin I-stimulated vasoconstriction in the rabbit femoral artery and sarafotoxin 6c-stimulated vasoconstriction in the rabbit pulmonary artery with pA2 values of 0.00025 and 0.34, resp. The experimental process involved the reaction of Methyl 2-(3-formylphenyl)acetate(cas: 142327-44-4).Quality Control of Methyl 2-(3-formylphenyl)acetate

The Article related to acute renal failure, angina pectoris, antiarrhythmics, antiasthmatics, antiatherosclerotics, antidiabetic agents, antihypertensives, antitumor agents, benign prostatic hyperplasia, brain infarction, brain ischemia, cerebral artery spasm, chronic renal failure, cirrhosis, coronary restenosis, gastric mucosa (damage), heart failure and other aspects.Quality Control of Methyl 2-(3-formylphenyl)acetate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

In 2019,Angewandte Chemie, International Edition included an article by Wang, Zhe; Xue, Fei; Hayashi, Tamio. Safety of Vinylene carbonate. The article was titled 《Synthesis of Arylacetaldehydes by Iridium-Catalyzed Arylation of Vinylene Carbonate with Arylboronic Acids》. The information in the text is summarized as follows:

Arylacetaldehydes were prepared by arylation of vinylene carbonate with arylboronic acids in the presence of [Ir(cod)(OMe)]2, 1,3-bis[di(4-methoxyphenyl)phosphino]propane, and B2(OH)4 in aqueous 1,2-dichloroethane. The experimental part of the paper was very detailed, including the reaction process of Vinylene carbonate(cas: 872-36-6Safety of Vinylene carbonate)

Vinylene carbonate(cas: 872-36-6) belongs to esters. Alkyl carbonates find applications as solvents for lithium ion battery electrolytes and the use of high quality battery grade electrolytes having extremely low water (<10 ppm) and acid (<10 ppm) contents are critical for achieving high electrochemical performance.Safety of Vinylene carbonate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

In 2019,European Journal of Organic Chemistry included an article by Baron, Marco; Biffis, Andrea. Electric Literature of C5H6O2. The article was titled 《Gold(I) Complexes in Ionic Liquids: An Efficient Catalytic System for the C-H Functionalization of Arenes and Heteroarenes under Mild Conditions》. The information in the text is summarized as follows:

Use of ionic liquids bearing the proper counteranion as reaction solvents allows to boost the reactivity of gold(I) complexes as catalysts in the hydroarylation of alkynes with arenes and heteroarenes. Several com. complexes of general structure LAuX have been tested as catalysts, with L=1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene standing out as the one delivering the best performance. Beside high activity, enabling the use of <1 mol-% catalyst under mild conditions (low temperature, no need for an acid cocatalyst), gold-based catalytic systems in ionic liquids also exhibit tunable chemo- and regioselectivity in these reactions and turn out to be recyclable, which renders them quite attractive for synthetic applications. In the part of experimental materials, we found many familiar compounds, such as Ethyl propiolate(cas: 623-47-2Electric Literature of C5H6O2)

Ethyl propiolate(cas: 623-47-2) is a clear colorless to pale yellow liquid that is soluble in ethanol, ether and chloroform. It an important organic chemical raw material and pharmaceutical intermediate. Ethyl propargylate is obtained by oxidation of propargyl alcohol to propargylic acid followed by esterification.Electric Literature of C5H6O2

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics